Sponsor: Merck
Sponsor Study ID: MK-7902-009
Study Title: A Phase 2, randomized, open label three arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK 7902) in combination with pembrolizumab (MK 3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD 1/PD L1 inhibitors) (LEAP 009)
CTO #: 103262
NCT Number: NCT04428151
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lip, Oral Cavity and Pharynx, Larynx
Study Objectives: To compare lenvatinib + pembrolizumab combination therapy and SOC chemotherapy with respect to ORR per RECIST 1.1 as assessed by BICR.